News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Incyte Corporation Reviews Positive Proof-of-Concept Clinical Results Achieved During the Third Quarter
November 1, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY - News) today reviewed its drug discovery and development programs and reported third quarter 2007 financial results.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Obesity
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
April 15, 2026
·
2 min read
·
Tristan Manalac
Podcast
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
April 15, 2026
·
1 min read
·
Heather McKenzie
Gene editing
FDA bolsters bespoke therapy framework with new draft safety guidelines
April 14, 2026
·
2 min read
·
Gabrielle Masson
Antibody-drug conjugate (ADC)
BioNTech, DualityBio tout ‘clinically meaningful’ efficacy for ADC in mid-stage endometrial cancer trial
April 13, 2026
·
2 min read
·
Tristan Manalac
